NANO Nanobiotix SA

NANOBIOTIX to Participate in Investor Conferences in March

NANOBIOTIX to Participate in Investor Conferences in March

PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March:

TD Cowen's Health Care Conference

Date: Wednesday, March 4, 2026

Location: Boston, MA

Time of the fireside chat: 11:10am ET / 5:10pm CET

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

UBS Biotech Summit Miami

Date: Monday, March 9, 2026

Location: Miami Beach, FL

Jefferies Biotech on the Beach Summit

Date: Tuesday, March 10, 2026

Location: Miami Beach, FL

Leerink's Global Healthcare Conference

Date: Wednesday, March 11, 2026

Location: Miami Beach, FL

Time of the fireside chat: 2:20pm EDT / 7:20pm CET

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at or follow us on and .

Contacts

Nanobiotix
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

Investor Relations Department



Joanne Choi

VP, Investor Relations (US)

+1 (713) 609-3150



Ricky Bhajun

Director, Investor Relations (EU)

+33 (0) 79 97 29 99







Media Relations


France – HARDY

Caroline Hardy

50







Global – uncapped

Becky Lauer

+1 (646) 286-0057

  

  Attachment



EN
25/02/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
 PRESS RELEASE

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financi...

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerClinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of spo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch